MedTrace Logo

A Trial to Evaluate Faropenem Medoxomil in the Treatment of Acute Otitis Media

NCT00276042 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 328

Last updated 2008-02-08

No results posted yet for this study

Summary

The study will be conducted in infants and children with acute otitis media, 6 months to less than 7 years old, in Costa Rica and Israel. The primary objective of this trial will be to describe bacteriologic efficacy in those with initial culture positive specimens with different dosages of faropenem

Conditions

  • Otitis Media

Interventions

DRUG

Faropenem Medoxomil

Sponsors & Collaborators

  • Replidyne

    lead INDUSTRY

Principal Investigators

  • Roger M Echols, MD · Replidyne, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
7 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2007-01-31

Countries

  • Costa Rica
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00276042 on ClinicalTrials.gov